Y-Intercept (Hong Kong) 13F: Cuts BSX Stake by $43M
Y-Intercept (Hong Kong) reduced its holdings in Boston Scientific Corporation by 88.7%, leaving it with 126,685 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Y-Intercept (Hong Kong) sold 993,646 shares from its stake in Boston Scientific Corporation ($BSX), an 88.69% decrease, according to a 13F filing with the SEC dated October 16, 2026. It reported 126,685 shares worth $5.53 million at the end of the quarter.
Find the original: Y-Intercept (Hong Kong) 13F filings on SEC EDGAR
BSX
Boston Scientific Corporation
Key Points
- Y-Intercept (Hong Kong) cut its position in Boston Scientific Corporation by 993,646 shares, leaving a total of 126,685 shares worth about $5.5 million in a filing on October 16, 2026.
- The stock recently traded near $44.20, sitting below its 50-day and 200-day moving averages as investors look toward the upcoming October 28 earnings report.
- Company insiders recently purchased shares over the summer, while Wall Street analysts maintain a consensus buy rating on the medical device maker.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Y-Intercept (Hong Kong) scaled back its investment in Boston Scientific Corporation (NYSE:BSX), trimming its holdings by 88.7% during the period covered in a Form 13F filed with the SEC on October 16, 2026. Keep in mind that 13F reports look backward at positions held at the close of a quarter and might not reflect what the fund holds today.
What Changed in Y-Intercept (Hong Kong)'s Boston Scientific Corporation Position
The fund parted ways with 993,646 shares of the medical device maker, leaving it with 126,685 shares. The remaining stake carried a reported value of $5.5 million at the close of the period, down from its prior holding of 1,120,331 shares.
Other Institutional Activity in Boston Scientific Corporation
Blackrock Inc. reduced its holdings by 2,135,425 shares, ending with 129,680,916 shares worth about $5.8 billion. Vanguard Capital Management LLC grew its holdings by 674,889 shares, ending with 97,087,553 shares worth about $4.3 billion. State Street Corporation grew its holdings by 2,121,285 shares, ending with 70,111,196 shares worth about $3.1 billion. Primecap Management Company grew its holdings by 17,991,834 shares, ending with 50,520,914 shares worth about $2.2 billion. FMR, LLC reduced its holdings by 28,526,236 shares, ending with 45,702,845 shares worth about $2.0 billion.
Boston Scientific Corporation Stock Up 2.8%
Boston Scientific shares recently traded around $44.20 on October 16, 2026. The stock trades below its 50-day moving average of $46.18 and well below its 200-day moving average of $59.36. The 52-week trading range spans from a low of $41.39 to a high of $105.65.
Recent Earnings
Boston Scientific generated trailing-twelve-month revenue of $21.0 billion alongside trailing earnings of $2.47 per share. The company reported a net profit margin of 17.5% and a return on equity of 15.3%. The next earnings release is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Chief Executive Officer Michael F. Mahoney bought 186,240 shares on August 3, 2026, at an average price of $48.33 for a total value of $9.0 million. Director David C. Habiger picked up 1,182 shares on August 4, 2026, followed by another purchase of 2,100 shares on August 5, 2026, at $47.59 per share for a total of $99,937. Director Susan E. Morano bought 2,040 shares on August 25, 2026, at $49.22 per share for a value of $100,408.
Analysts Set New Price Targets
Oppenheimer maintained an outperform rating on September 21, 2026, adjusting its price target to $65.00. Wells Fargo maintained an equal-weight rating on September 24, 2026, lowering its target to $48.00. Citigroup maintained a neutral rating on October 5, 2026, setting a target of $48.00. Barclays initiated coverage with an equal-weight rating and a $48.00 target on October 7, 2026. Truist Securities maintained a buy rating on October 14, 2026, trimming its target to $51.00. Overall, the stock holds a consensus buy rating with a mean price target of $59.24 across 29 analyst opinions.
About Boston Scientific Corporation
Boston Scientific Corporation invents, builds, and distributes specialized medical devices used by physicians in interventional specialties around the globe. Its operations focus on cardiovascular care and broad MedSurg applications, supporting clinicians who treat complex patient conditions.
Bottom Line
Institutional investors continuously adjust their portfolios based on changing market conditions, and this filing simply shows where Y-Intercept stood at the end of the quarter. Investors will look to the upcoming earnings report on October 28, 2026, for fresh details on the company's financial trajectory. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.
Related Filing Alerts
Source: Y-Intercept (Hong Kong)'s 13F filing on $BSX (Oct 16, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Y-Intercept (Hong Kong) 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts